¼¼°èÀÇ ÆÄŬ¸®Å¹¼¿(Paclitaxel) ÁÖ»çÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Paclitaxel Injection Global Market Report 2025
»óǰÄÚµå : 1694708
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÆÄŬ¸®Å¹¼¿ ÁÖ»çÁ¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö CAGR 12.9%·Î 111¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý, ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß, °í·ÉÈ­¿¡ µû¸¥ ¾Ï ºÎ´ã Áõ°¡, ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü, ÇコÄɾî Á¤Ã¥ÀÇ º¯È­ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Á¾¾çÇп¡¼­ÀÇ AI ÅëÇÕ, ¿ø°ÝÀÇ·á ¹× ¿ø°Ý ÇコÄÉ¾î ¼­ºñ½º, ¾à¹° Àü´Þ ±â¼ú Çõ½Å, ¾à¹° Àü´Þ ±â¼úÀÇ ÅëÇÕ, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ºÎ»ó µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

¿¹»óµÇ´Â À¯¹æ¾Ï »ç·Ê Áõ°¡´Â ÇâÈÄ ÆÄŬ¸®Å¹¼¿ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯¹æ¾ÏÀº À¯¹æÀÇ ºñÁ¤»óÀûÀÎ ¼¼Æ÷ Áõ½ÄÀ» Ư¡À¸·Î Çϸç, Á¾Á¾ Á¾¾çÀ» Çü¼ºÇϰí À¯ÇàÇÏ´Â ÁúȯÀÔ´Ï´Ù. È­Çпä¹ýÀÎ ÆÄŬ¸®Å¹¼¿ ÁÖ»çÁ¦´Â ¹Ì¼¼Ç÷°ü¿¡ °áÇÕÇÏ¿© ¾Ï¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÔÀ¸·Î½á À¯¹æ¾Ï Ä¡·á¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¹Ì±¹¾ÏÇùȸÀÇ 2023³â 1¿ù ÃßÁ¤¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 2023³â ħÀ±¼º À¯¹æ¾Ï ½Å±Ô ȯÀÚ°¡ ¾à 297,790¸í, 2023³â¿¡´Â ¾à 43,700¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ À¯¹æ¾Ï ¹ßº´·ü Áõ°¡´Â ÆÄŬ¸®Å¹¼¿ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù.

¾Ï ¹ßº´·ü Áõ°¡´Â ÇâÈÄ ÆÄŬ¸®Å¹¼¿ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ã¹è¿Í ¾ËÄÚ¿Ã ¼Òºñ Áõ°¡, Èí¿¬ÀÇ È®»ê µîÀÇ ¿äÀÎÀÌ Àü ¼¼°è ¾Ï ȯÀÚ ¼ö Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÆÄŬ¸®Å¹¼¿Àº À¯¹æ¾Ï, Æó¾Ï, ³­¼Ò¾Ï µî ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ´Â È­Çпä¹ýÁ¦ÀÔ´Ï´Ù. ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó È­Çпä¹ý¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÆÄŬ¸®Å¹¼¿Àº ¸¹Àº Ä¡·á ¿ä¹ý¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù, ¾Ï ¿¬±¸ ¹× ±³À°¿¡ ÁßÁ¡À» µÐ Á¤ºÎ ±â°üÀÎ ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò´Â 2040³â±îÁö Àü ¼¼°è ¿¬°£ ½Å±Ô ¾Ï ȯÀÚ ¼ö°¡ 2,990¸¸ ¸í¿¡ ´ÞÇÏ°í ¾Ï °ü·Ã »ç¸ÁÀÚ ¼ö°¡ 1,530¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. µû¶ó¼­ ¾Ï ¹ß»ý·ü Áõ°¡´Â ÆÄŬ¸®Å¹¼¿ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Paclitaxel injection is a chemotherapy drug used in cancer treatment, typically administered through infusion into a vein in a hospital or clinic by a trained healthcare professional. Its mechanism of action involves disrupting the division and growth of cancer cells, ultimately leading to their destruction.

The primary types of paclitaxel injection are natural paclitaxel and semi-synthetic paclitaxel. Natural paclitaxel is a tetracyclic diterpenoid initially extracted from sources such as the bark of the Pacific yew tree, Taxus brevifolia. It is available in various drug strengths, including 10mg/ml, 20mg/ml, and 30mg/ml, and is utilized for the treatment of various cancers such as breast cancer, prostate cancer, testicular cancer, non-small cell lung cancer, lung cancer, among others. These injections are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are used by end-users such as hospitals, clinics, and cancer research institutes.

The paclitaxel injection market research report is one of a series of new reports from The Business Research Company that provides paclitaxel injection market statistics, including paclitaxel injection industry global market size, regional shares, competitors with a paclitaxel injection market share, detailed paclitaxel injection market segments, market trends and opportunities, and any further data you may need to thrive in the paclitaxel injection industry. This paclitaxel injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The paclitaxel injection market size has grown rapidly in recent years. It will grow from $6.02 billion in 2024 to $6.87 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to clinical research and trials, increasing incidence of cancer, patient awareness and education, globalization of pharmaceutical industry.

The paclitaxel injection market size is expected to see rapid growth in the next few years. It will grow to $11.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to personalized medicine approaches, biosimilar development, rising cancer burden in aging population, advancements in drug delivery systems, healthcare policy changes. Major trends in the forecast period include integration of ai in oncology, telemedicine and remote healthcare services, technological innovations in drug delivery, integration of drug delivery technologies, rise of biosimilars.

The anticipated rise in breast cancer cases is poised to drive the growth of the paclitaxel injection market in the future. Breast cancer, characterized by abnormal cell growth in the breast, often forming tumors, is a prevalent condition. Paclitaxel injection, a chemotherapy drug, is instrumental in treating breast cancer by binding to microtubules, disrupting the growth of cancer cells. According to the American Cancer Society's January 2023 estimate, approximately 297,790 new cases of invasive breast cancer are expected in the US, leading to an estimated 43,700 deaths in 2023. Thus, the increasing incidence of breast cancer is a significant factor propelling the growth of the paclitaxel injection market.

The increasing incidence of cancer is anticipated to drive the growth of the paclitaxel injection market in the future. Factors such as the rising consumption of tobacco and alcohol, along with the prevalence of smoking, are contributing to the growing number of cancer cases worldwide. Paclitaxel is a chemotherapy drug widely used to treat various cancers, including breast, lung, and ovarian cancer. As the number of cancer cases rises, there will be a higher demand for chemotherapy, with paclitaxel being an essential part of many treatment regimens. For example, in May 2024, the National Cancer Institute, a US-based government agency focused on cancer research and training, projected that the global number of new cancer cases per year is expected to reach 29.9 million, along with 15.3 million cancer-related deaths by 2040. Therefore, the increasing incidence of cancer is propelling the growth of the paclitaxel injection market.

Leading companies in the paclitaxel injection market are focusing on developing innovative products using advanced materials, such as protein-bound particles, to deliver reliable services to consumers. Protein-bound particles (PBPs) represent a drug delivery system that employs albumin, a naturally occurring blood protein, to bind with a drug. For example, in April 2022, Apotex Corp, a US-based pharmaceutical firm, introduced Paclitaxel protein-bound particles for injection (albumin-bound), a generic alternative to Abraxane for the first-line treatment of locally advanced or metastatic non-small cell lung cancer and for metastatic breast cancer. This formulation is administered through intravenous infusion and was launched by American Regent, Inc. as an alternative to Abraxane.

Key players in the paclitaxel injection market are also concentrating on developing innovative products, such as albumin-bound paclitaxel solutions, to broaden treatment options for patients with specific cancer types, offering potentially life-extending therapies. The albumin-bound paclitaxel solution is a solvent-free formulation of the chemotherapy drug paclitaxel, designed to improve drug delivery and minimize toxicity by using albumin nanoparticles to target tumor sites directly. For instance, in May 2023, American Regent, Inc., a US-based injectable manufacturer, launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), providing an alternative to Abraxane. This groundbreaking product functions as a microtubule inhibitor for the treatment of metastatic breast cancer, non-small cell lung cancer, and metastatic adenocarcinoma of the pancreas. Its significance lies in the potential to offer a life-extending treatment option for patients while aiding the company's expansion into the oncology market, further underscoring the importance of domestically manufactured medications.

Major companies operating in the paclitaxel injection market report are Pfizer Inc., Bristol-Myers Squibb Company, Fresenius Kabi Oncology Ltd., Abbott Laboratories, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hospira Inc., Dr. Reddy's Laboratories Ltd., Apotex Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Luye Pharma Group, Biological E Limited, Alembic Pharmaceuticals Limited, Khandelwal Laboratories Pvt. Ltd., Gland Pharma Limited, Abraxis Bio Science Inc., Novasep Holding SAS, Sagent Pharmaceuticals Inc., Hainan Haiyao Co Ltd., Accord Healthcare Ltd., Natco Pharma Limited, Strides Pharma Science Limited, Panacea Biotec Ltd., American Regent Inc., MSN Laboratories Pvt Ltd., Hetero Drugs Ltd.

North America was the largest region in the paclitaxel injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paclitaxel injection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the paclitaxel injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The paclitaxel injection market consists of sales of conventional paclitaxel injection, albumin-bound paclitaxel injection, nanoparticle albumin-bound paclitaxel, and liposomal paclitaxel. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paclitaxel Injection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paclitaxel injection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for paclitaxel injection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paclitaxel injection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Paclitaxel Injection Market Characteristics

3. Paclitaxel Injection Market Trends And Strategies

4. Paclitaxel Injection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Paclitaxel Injection Growth Analysis And Strategic Analysis Framework

6. Paclitaxel Injection Market Segmentation

7. Paclitaxel Injection Market Regional And Country Analysis

8. Asia-Pacific Paclitaxel Injection Market

9. China Paclitaxel Injection Market

10. India Paclitaxel Injection Market

11. Japan Paclitaxel Injection Market

12. Australia Paclitaxel Injection Market

13. Indonesia Paclitaxel Injection Market

14. South Korea Paclitaxel Injection Market

15. Western Europe Paclitaxel Injection Market

16. UK Paclitaxel Injection Market

17. Germany Paclitaxel Injection Market

18. France Paclitaxel Injection Market

19. Italy Paclitaxel Injection Market

20. Spain Paclitaxel Injection Market

21. Eastern Europe Paclitaxel Injection Market

22. Russia Paclitaxel Injection Market

23. North America Paclitaxel Injection Market

24. USA Paclitaxel Injection Market

25. Canada Paclitaxel Injection Market

26. South America Paclitaxel Injection Market

27. Brazil Paclitaxel Injection Market

28. Middle East Paclitaxel Injection Market

29. Africa Paclitaxel Injection Market

30. Paclitaxel Injection Market Competitive Landscape And Company Profiles

31. Paclitaxel Injection Market Other Major And Innovative Companies

32. Global Paclitaxel Injection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paclitaxel Injection Market

34. Recent Developments In The Paclitaxel Injection Market

35. Paclitaxel Injection Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â